Gene · 4481
Papers3,855
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,855
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Zoledronic acid attenuates ischemic brain injury by promoting ETS2 and MSR1 expression. | Int Immunol | 2025 | 40305406 | PubTator, text mining | PubMed |
| Localization of epidermal growth factor receptor-mutations using PNA:DNA probes in clinical specimens from patients with non-small cell lung cancer. | Sci Rep | 2025 | 40175465 | PubTator, text mining | PubMed |
| OTUB1 facilitates lipid accumulation in oxLDL-induced THP-1 macrophages by stabilizing scavenger receptor-A. | IUBMB Life | 2025 | 40114404 | PubTator, text mining | PubMed |
| Exploring the hepatic-ophthalmic axis through immune modulation and cellular dynamics in diabetic retinopathy and non-alcoholic fatty liver disease. | Hum Genomics | 2025 | 40011971 | PubTator, text mining | PubMed |
| Golden Tandem of Photothermal Ablation and Simultaneous Anti-Inflammation in One Nanoparticle for Activated Macrophage-Targeted Atherosclerosis Treatment. | Int J Nanomedicine | 2025 | 39936024 | PubTator, text mining | PubMed |
| Characterization of canine tumor-infiltrating leukocyte transcriptomic signatures reveals conserved expression patterns with human osteosarcoma. | Cancer Immunol Immunother | 2025 | 39932553 | PubTator, text mining | PubMed |
| Bronchoalveolar lavage single-cell transcriptomics reveals immune dysregulations driving COVID-19 severity. | PLoS One | 2025 | 39928675 | PubTator, text mining | PubMed |
| Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism. | Nat Commun | 2025 | 39900573 | PubTator, text mining | PubMed |
| Immunostimulatory Effects of Guanine-Quadruplex Topologies as Scaffolds for CpG Oligodeoxynucleotides. | Biomolecules | 2025 | 39858489 | PubTator, text mining | PubMed |
| Combined Molecular Subclass and Immune Phenotype Correlate to Atezolizumab Plus Radiation Therapy Response in Invasive Bladder Cancer: BPT-ART Phase 2 Study. | Int J Radiat Oncol Biol Phys | 2025 | 39755215 | PubTator, text mining | PubMed |
| Large-scale multicenter study reveals anticitrullinated SR-A peptide antibody as a biomarker and exacerbator for rheumatoid arthritis. | Sci Adv | 2025 | 39752500 | PubTator, text mining | PubMed |
| A topographic approach to the markers of macrophage/microglia and other cell types in high grade glioma. | Neurochem Int | 2025 | 39734023 | PubTator, text mining | PubMed |
| Metal-organic framework-based nanoplatforms for synergistic anti-atherosclerosis therapy by regulating the PI3K/AKT/MSR1 pathway in macrophages. | Nanoscale | 2025 | 39704073 | PubTator, text mining | PubMed |
| MSR1 in lung squamous cell carcinoma: Prognostic and immunological values in pan-cancer and single-cell analyses and a cohort study. | Int Immunopharmacol | 2025 | 39667048 | PubTator, text mining | PubMed |
| Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy. | Prostate | 2025 | 39580660 | PubTator, text mining | PubMed |
| Plasma Protein Biomarkers of Spirometry Measures of Impaired Lung Function. | Chest | 2025 | 39580111 | PubTator, text mining | PubMed |
| Combination of scavenger receptor-A with anti-cyclic citrullinated peptide antibody for the diagnosis of rheumatoid arthritis. | Rheumatology (Oxford) | 2025 | 38781519 | PubTator, text mining | PubMed |
| Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis. | Pharm Sci Adv | 2024 | 41550179 | PubTator, text mining | PubMed |
| The regulation of cancer-associated thrombosis by podoplanin. | Thromb Update | 2024 | 40741180 | PubTator, text mining | PubMed |
| Combinatory actions of cytokines induce M2-like macrophages in anaplastic thyroid cancer. | Am J Cancer Res | 2024 | 39803637 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4481/papers?page=7